Arsenal Capital Partners schließt Übernahme von Cyalume Technologies ab
Originaltitel: Arsenal Capital Partners Completes Acquisition of Cyalume Technologies
KI-Zusammenfassung
Die New Yorker Private-Equity-Gesellschaft Arsenal Capital Partners hat die Übernahme von Cyalume Technologies abgeschlossen. Das Unternehmen stellt Spezialchemikalien und Komponenten unter anderem für militärische, pharmazeutische und kommerzielle Märkte her. Unter dem neuen Eigentümer soll das Wachstum durch organische Initiativen sowie gezielte Zukäufe vorangetrieben werden.
Automatisch ins Deutsche übersetzt
Kernaussagen
Arsenal Capital Partners erwirbt den Spezialchemie- und Komponentenhersteller Cyalume Technologies
Cyalume beliefert neben dem zivilen Markt auch militärische Kunden mit Technologieprodukten
Geplante Wachstumsstrategie umfasst weitere Übernahmen in Kern- und Nachbarmärkten
Volltext aus dem RSS-Feed
Unverändert aus dem öffentlichen RSS-Feed von Cyalume Technologies übernommen. Alle Rechte liegen bei der Originalquelle. Zum Original bei Cyalume Technologies
NEW YORK, September 18, 2017 – Arsenal Capital Partners (“Arsenal”), a leading New York-based private equity firm that invests in middle-market specialty industrials and healthcare companies, announced today the acquisition of Cyalume Technologies (“Cyalume”), a leading specialty chemicals provider to diversified end markets. Cyalume produces specialty chemicals and pharmaceutical components, designs and manufactures unique related products, and manufactures components for use in pharmaceutical, medical, commercial and military markets. The company is headquartered in Ft. Lauderdale, FL and has manufacturing locations in West Springfield, MA and Bound Brook, NJ as well as a subsidiary, Cyalume Technologies, SAS located in Aix-en-Provence, France. Zivi Nedivi, Cyalume’s President and CEO, commented, “We look forward to the partnership with Arsenal to enhance our portfolio of technologies and operating capabilities. Cyalume participates in a number of fragmented markets, such as specialty chemicals and pharmaceutical ingredients, and we expect to capitalize on our position through a robust acquisition strategy.” “We look forward to supporting the company’s organic and acquisition initiatives. Consistent with other Arsenal investments, Cyalume will pursue a buy and build strategy in its core and adjacent markets while continuing its focus on customers and innovation,” said Sal Gagliardo, Industry and Operations Partner at Arsenal and Chairman of Cyalume. Cyalume represents Arsenal’s second Specialty Industrials investment in 2017 following its acquisition of PolyOne Corporation’s Designed Structures and Solutions business in July 2017. About Arsenal Capital Partners Established in 2000, Arsenal Capital Partners is a leading New York based private equity firm that specializes in investments in middle market specialty industrials and healthcare companies. Since inception, Arsenal has raised institutional equity investment funds of approximately $3 billion. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience and seeks companies typically in the range of $100 – $500 million of initial enterprise value. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For additional information on Arsenal Capital Partners, please visit www.arsenalcapital.com .